GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HLscience Co Ltd (XKRX:239610) » Definitions » Cash-to-Debt

HLscience Co (XKRX:239610) Cash-to-Debt : 59.55 (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is HLscience Co Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. HLscience Co's cash to debt ratio for the quarter that ended in Mar. 2024 was 59.55.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, HLscience Co could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for HLscience Co's Cash-to-Debt or its related term are showing as below:

XKRX:239610' s Cash-to-Debt Range Over the Past 10 Years
Min: 59.55   Med: 5594.25   Max: 28393.81
Current: 59.55

During the past 9 years, HLscience Co's highest Cash to Debt Ratio was 28393.81. The lowest was 59.55. And the median was 5594.25.

XKRX:239610's Cash-to-Debt is ranked better than
86.23% of 1002 companies
in the Drug Manufacturers industry
Industry Median: 0.96 vs XKRX:239610: 59.55

HLscience Co Cash-to-Debt Historical Data

The historical data trend for HLscience Co's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

HLscience Co Cash-to-Debt Chart

HLscience Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only 668.55 1,354.37 2,367.01 10,033.58 No Debt

HLscience Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28,393.81 No Debt No Debt No Debt 59.55

Competitive Comparison of HLscience Co's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, HLscience Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HLscience Co's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, HLscience Co's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where HLscience Co's Cash-to-Debt falls into.



HLscience Co Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

HLscience Co's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

HLscience Co had no debt (1).

HLscience Co's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HLscience Co  (XKRX:239610) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


HLscience Co Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of HLscience Co's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


HLscience Co (XKRX:239610) Business Description

Traded in Other Exchanges
N/A
Address
36, Dongsanjae-gil, Bongdam-eup, Hwaseong-si, Gyeonggi-do, Anyang-si, KOR
HLscience Co Ltd is engaged in researching and developing bio healthcare products. It offers products including Dr. Super Khan, Red Cleo, Dr. Spirulina, Dr. Circuone, and Super We Force.

HLscience Co (XKRX:239610) Headlines

No Headlines